Open-label, single center, phase I trial to investigate the mass balance and absolute bioavailability of the oral c-Met inhibitor tepotinib

被引：0
|
作者：
Johne, A. [1 ]
Scheible, H. [2 ]
Becker, A. [1 ]
Van Lier, J. J. [3 ]
Meyring, M. [2 ]
机构：
[1] Merck KGaA, Global Early Dev, Darmstadt, Germany
[2] Merck KGaA, Inst Drug Metab & Pharmacokinet, Grafing, Germany
[3] Pharmaceut Res Assoc, Early Dev Serv, Zuidlaren, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30232-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
369
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [41] Absorption, metabolism, and excretion of oral [14C] radiolabeled donafenib: an open-label, phase I, single-dose study in humans
    Ma, Sheng
    Yi, Ling
    Bian, Yicong
    Lv, Binhua
    Zhang, Cong
    Li, Chengwei
    Zhang, Hua
    Miao, Liyan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [42] PHASE I DOSE ESCALATION TRIAL OF SELECTIVE C-MET INHIBITOR ARQ 197 IN JAPANESE PATIENTS WITH METASTATIC SOLID TUMORS
    Yamamoto, N.
    Takahashi, T.
    Naito, T.
    Murakami, H.
    Yasui, H.
    Koh, Y.
    Saito, Y.
    Maeda, H.
    Akinaga, S.
    Boku, N.
    ANNALS OF ONCOLOGY, 2010, 21 : 166 - 167
  • [43] A novel approach for wound treatment using dried cultured epidermal allograft: A phase I/II, single-center, open-label clinical trial
    Sakamoto, Michiharu
    Minaki, Yasuko
    Nakano, Takashi
    Tsuge, Itaru
    Yamanaka, Hiroki
    Sowa, Yoshihiro
    Shimizu, Yoshihiro
    Inoie, Masukazu
    Saito, Susumu
    Morimoto, Naoki
    BURNS, 2023, 49 (05) : 1079 - 1086
  • [44] A phase II trial investigating the highly selective c-Met inhibitor tepotinib in stage IIIB/IV lung adenocarcinoma with MET exon 14 alterations after failure of at least one prior therapy
    Paik, P. K.
    Stammberger, U.
    Bruns, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
    Aghajanian, Carol
    Bell-McGuinn, Katherine M.
    Burris, Howard A., III
    Siu, Lillian L.
    Stayner, Lee-Ann
    Wheler, Jennifer J.
    Hong, David S.
    Kurkjian, Carla
    Pant, Shubham
    Santiago-Walker, Ademi
    Gauvin, Jennifer L.
    Antal, Joyce M.
    Opalinska, Joanna B.
    Morris, Shannon R.
    Infante, Jeffrey R.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1016 - 1025
  • [46] A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
    Carol Aghajanian
    Katherine M. Bell-McGuinn
    Howard A. Burris
    Lillian L. Siu
    Lee-Ann Stayner
    Jennifer J. Wheler
    David S. Hong
    Carla Kurkjian
    Shubham Pant
    Ademi Santiago-Walker
    Jennifer L. Gauvin
    Joyce M. Antal
    Joanna B. Opalinska
    Shannon R. Morris
    Jeffrey R. Infante
    Investigational New Drugs, 2018, 36 : 1016 - 1025
  • [47] A rapid and sensitive LC-MS/MS method for evaluation of the absolute oral bioavailability of a novel c-Met tyrosine kinase inhibitor QBH-196 in rats
    Zhang, Qi.
    Sun, Jin
    Lu, Tianshu
    Zhang, Jinling
    Wu, Chunnuan
    Li, Lin
    He, Zhonggui
    Zhao, Yanfang
    Liu, Xiaohong
    BIOMEDICAL CHROMATOGRAPHY, 2015, 29 (11) : 1650 - 1656
  • [48] A Phase I Dose-escalation Study of EMD 1214063, an Oral Selective C-Met Inhibitor, in Patients With Advanced Solid Tumours
    Falchook, G. S.
    Fu, S.
    Amin, H. M.
    Piha-Paul, S. A.
    Hong, D. S.
    Naing, A.
    Klevesath, M. B.
    Mattiacci, M. R.
    Di Cara, A.
    Kurzrock, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S158 - S158
  • [49] PHASE I DOSE-ESCALATION STUDY OF ORAL SELECTIVE C-MET INHIBITOR EMD 1214063 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Falchook, G. S.
    Hong, D. S.
    Amin, H. M.
    Fu, S.
    Piha-Paul, S. A.
    Klevesath, M. B.
    Jego, V.
    Johne, A.
    Stinchi, S.
    Kurzrock, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 154 - 154
  • [50] A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
    Hasegawa, Hirotaka
    Shitara, Kohei
    Takiguchi, Shuji
    Takiguchi, Noriaki
    Ito, Seiji
    Kochi, Mitsugu
    Horinouchi, Hidehito
    Kinoshita, Takahiro
    Yoshikawa, Takaki
    Muro, Kei
    Nishikawa, Hiroyoshi
    Suna, Hideaki
    Kodera, Yasuhiro
    GASTRIC CANCER, 2022, 25 (03) : 619 - 628
12345